Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting

被引：6
|
作者：
Tan, Jiaxiong [1 ,2 ]
Tan, Huo [1 ]
Li, Yangqiu [2 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 5, Dept Hematol, Guangzhou 510700, Peoples R China
[2] Jinan Univ, Inst Hematol, Sch Med, Key Lab Regenerat Med,Minist Educ, Guangzhou 510632, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2023年 / 12卷 / 01期
基金：
中国国家自然科学基金;
关键词：
TIM-3; Gal-9; Immunotherapy; Hematological malignancies;
D O I：
10.1186/s40164-023-00421-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
T cell immunoglobulin domain and mucin domain-3 (TIM-3) is an important immune checkpoint (IC) protein in cancer immunosuppression that is considered a novel target for immunotherapy. Moreover, TIM-3, an immuno-myeloid regulator, is highly expressed on the cells of several solid tumors and myeloid leukemia stem cells (LSCs). TIM-3 blockade was shown to have dual effects for directly inhibiting leukemia cells and restoring T cell activation. We summarize several of the latest reports on the role of TIM-3 in immunotherapy for hematological malignancies from the 2022 ASH Annual Meeting (ASH2022).
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting
    Jiaxiong Tan
    Huo Tan
    Yangqiu Li
    Experimental Hematology & Oncology, 12
  • [2] Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
    Yang Cao
    Emanuela C. Marcucci
    Lihua E. Budde
    Journal of Hematology & Oncology, 16
  • [3] Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
    Cao, Yang
    Marcucci, Emanuela C.
    Budde, Lihua E.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [4] Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting
    Yin, Xuejiao
    Liu, Yi
    Sun, Jianai
    Tong, Hongyan
    Meng, Haitao
    You, Liangshun
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14
  • [5] Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting
    DiNardo, Katherine W. W.
    LeBlanc, Thomas W. W.
    Chen, Hui
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [6] Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting
    Katherine W. DiNardo
    Thomas W. LeBlanc
    Hui Chen
    Journal of Hematology & Oncology, 16
  • [7] Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
    Jieyun Xia
    Zhenyu Li
    Kailin Xu
    Journal of Hematology & Oncology, 16
  • [8] Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
    Xia, Jieyun
    Li, Zhenyu
    Xu, Kailin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [9] Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
    Wang, Chaoyu
    Liu, Yao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [10] Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
    Chaoyu Wang
    Yao Liu
    Journal of Hematology & Oncology, 16
12345